Department of Biochemistry, Biology & Genetics, Marche Polytechnic University, Ancona, Italy.
Biofactors. 2011 Sep-Oct;37(5):366-73. doi: 10.1002/biof.154. Epub 2011 Jun 14.
Since the time a precise role of coenzyme Q(10) (CoQ(10) ) in myocardial bioenergetics was established, the involvement of CoQ in the pathophysiology of heart failure was hypothesized. This provided the rationale for numerous clinical trials of CoQ(10) as adjunctive treatment for heart failure. A mild hypotensive effect of CoQ was reported in the early years of clinical use of this compound. We review early human and animal studies on the vascular effects of CoQ. We then focus on endothelial dysfunction in type 2 diabetes and the possible impact on this condition of antioxidants and nutritional supplements, and in particular the therapeutic effects of CoQ. The effect of CoQ(10) on endothelial dysfunction in ischemic heart disease is also reviewed together with recent data highlighting that treatment with CoQ(10) increases extracellular SOD activity.
自从辅酶 Q(10)（CoQ(10)）在心肌生物能量学中的精确作用被确定以来，人们假设 CoQ 参与心力衰竭的病理生理学。这为大量临床试验提供了依据，即 CoQ(10)作为心力衰竭的辅助治疗。在这种化合物早期的临床应用中，报告了 CoQ 的轻度降压作用。我们回顾了关于 CoQ 的血管作用的早期人类和动物研究。然后，我们专注于 2 型糖尿病中的内皮功能障碍以及抗氧化剂和营养补充剂对这种情况的可能影响，特别是 CoQ 的治疗效果。我们还回顾了 CoQ(10)对缺血性心脏病中内皮功能障碍的影响，以及最近的数据强调 CoQ(10)治疗可增加细胞外 SOD 活性。
